US Bancorp’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

US Bancorp’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,648	Closed	-$124K	–	4316
2022 Q2	$124K	Buy	1,648 +505	+44%	+$22.4K	﹤0.01%	2123
2022 Q1	$31K	Buy	1,143 +666	+140%	+$22.4K	﹤0.01%	2849
2021 Q4	$23K	Buy	477 +149	+45%	+$6.66K	﹤0.01%	3048
2021 Q3	$22K	Buy	328 +14	+4%	+$997	﹤0.01%	3099
2021 Q2	$24K	Buy	314 +185	+143%	+$13.7K	﹤0.01%	3050
2021 Q1	$12K	Buy	129 +13	+11%	+$1.55K	﹤0.01%	3232
2020 Q4	$14K	Sell	116 -3	-3%	-$329	﹤0.01%	3070
2020 Q3	$10K	Buy	119 +25	+27%	+$1.74K	﹤0.01%	3101
2020 Q2	$6K	Buy	+94	New	+$5.42K	﹤0.01%	3282

US Bancorp's TPTX Position: Q3 2022 in Review

US Bancorp sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 1,648 shares — an estimated $124K sold.

US Bancorp first reported a position in TPTX in Q2 2020 and held it in 9 quarters. The position peaked at $124K in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

US Bancorp reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
US Bancorp sold 1,648 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $124K.
US Bancorp first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and held it in 9 quarters.
US Bancorp's Turning Point Therapeutics, Inc. Common Stock position peaked at $124K in Q2 2022.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on US Bancorp's 13F filing for Q3 2022, filed 27 Oct 2022.